

## Identification of small molecule modulators of reactive oxygen release in TNF- $\alpha$ primed primary human neutrophils.

### Introduction

Neutrophils are components of the innate immune system with an important role in the protection against external microorganisms. Neutrophils in circulating blood are normally in a resting state, but a number of inflammatory mediators can change them into an active state by a priming procedure. Activation triggers the adhesion and penetration of neutrophils into inflamed tissue, where reactive oxygen species (ROS) are released through the activation of NADPH oxidase.

Tumor necrosis factor alpha (TNF- $\alpha$ ) is one of the earliest cytokines produced at an inflammatory site. TNF- $\alpha$  itself does not activate NADPH oxidase in neutrophils to a great extent, but acts as a priming agent. Upon addition of the actin filament disrupting agent cytochalasin B to TNF- $\alpha$  primed neutrophils, a burst of released ROS is observed, with a timing and magnitude profile resembling that observed following stimulation of pro-inflammatory GPCRs expressed on the neutrophil surface.

We took advantage of this phenomenon and developed a screening assay aiming at identifying modulators of ROS release in TNF- $\alpha$  primed primary human neutrophils, with the goal to find novel GPCR modulators amongst the hits.

### Experimental procedure

Freshly isolated primary human neutrophils are first incubated with TNF- $\alpha$ . The cells are then triggered with cytochalasin B. The produced superoxide anions are measured by a chemiluminescence technique based on isoluminol using the single photon counting camera of the Hamamatsu FDSS 7000 EX.





Fig 1 : Screening Assay Logistics

## Results

A total of 7000 compounds were tested at a compound concentration of 1.3  $\mu$ M. MAPK (p38) and PI3K inhibitors are known to modulate several of the TNF- $\alpha$  induced effects. SB203580, a p38 inhibitor, and LY294002, a PI3K inhibitor, were used as reference compounds (Cf Fig 2).



SB203580 IC<sub>50</sub> 9 nM  
LY294002 IC<sub>50</sub> up to 1.6  $\mu$ M

One of the most potent hits  
SB202190 IC<sub>50</sub> 7 nM

Fig 2 : IC<sub>50</sub> curve of reference compound

## Conclusions

We demonstrated the successful transfer of a screening method to identify novel molecular targets (GPCR modulators, etc.) in inflammatory responses from a tube-based to a microplate-based format, allowing to get closer to a HTS method. A 7000 compounds small molecule library was screened in order to identify modulators of ROS release in TNF- $\alpha$  primed primary human neutrophils: 74 compounds were identified as inhibitors of ROS release in the experimental system.

**Acknowledgements:** CBCS (Chemical Biology Consortium Sweden) Karolinska Institutet, Stockholm Department of Rheumatology and Inflammation Research ; University of Gothenburg, Sweden

★ FDSS is registered trademark of Hamamatsu Photonics K.K. (China, France, Germany, Italy, Japan, U.K., U.S.A.)

★ Product and software package names noted in this documentation are trademarks or registered trademarks of their respective manufacturers.

- Subject to local technical requirements and regulations, availability of products included in this promotional material may vary. Please consult your local sales representative.
- Information furnished by HAMAMATSU is believed to be reliable. However, no responsibility is assumed for possible inaccuracies or omissions. Specifications and external appearance are subject to change without notice.

© 2015 Hamamatsu Photonics K.K.

**HAMAMATSU PHOTONICS K.K.** [www.hamamatsu.com](http://www.hamamatsu.com)

**HAMAMATSU PHOTONICS K.K., Systems Division**

**812 Joko-cho, Higashi-ku, Hamamatsu City, 431-3196, Japan, Telephone: (81)53-431-0124, Fax: (81)53-435-1574, E-mail: [export@sys.hpk.co.jp](mailto:export@sys.hpk.co.jp)**

**U.S.A.:** Hamamatsu Corporation: 360 Foothill Road, Bridgewater, N.J 08807, U.S.A., Telephone: (1)908-231-0960, Fax: (1)908-231-1218 E-mail: [usa@hamamatsu.com](mailto:usa@hamamatsu.com)

**Germany:** Hamamatsu Photonics Deutschland GmbH.: Arzbergerstr. 10, D-82211 Herrsching am Ammersee, Germany, Telephone: (49)8152-375-0, Fax: (49)8152-265-8 E-mail: [info@hamamatsu.de](mailto:info@hamamatsu.de)

**France:** Hamamatsu Photonics France S.A.R.L.: 19, Rue du Saule Trapu, Parc du Moulin de Massy, 91882 Massy Cedex, France, Telephone: (33)1 69 53 71 00, Fax: (33)1 69 53 71 10 E-mail: [infos@hamamatsu.fr](mailto:infos@hamamatsu.fr)

**United Kingdom:** Hamamatsu Photonics UK Limited: 2 Howard Court, 10 Tewin Road, Welwyn Garden City, Hertfordshire AL7 1BW, UK, Telephone: (44)1707-294888, Fax: (44)1707-325777 E-mail: [info@hamamatsu.co.uk](mailto:info@hamamatsu.co.uk)

**North Europe:** Hamamatsu Photonics Norden AB: Torshamnsgatan 35 16440 Kista, Sweden, Telephone: (46)8-509-031-00, Fax: (46)8-509-031-01 E-mail: [info@hamamatsu.se](mailto:info@hamamatsu.se)

**Italy:** Hamamatsu Photonics Italia S.r.l.: Strada della Moia, 1 int. 6 20020 Arese (Milano), Italy, Telephone: (39)02-93581733, Fax: (39)02-93581741 E-mail: [info@hamamatsu.it](mailto:info@hamamatsu.it)

**China:** Hamamatsu Photonics (China) Co., Ltd.: B1201 Jiaming Center, No.27 Dongsanhuan Beilu, Chaoyang District, Beijing 100020, China, Telephone: (86)10-6586-6006, Fax: (86)10-6586-2866 E-mail: [hpc@hamamatsu.com.cn](mailto:hpc@hamamatsu.com.cn)